News
SalvaRx Group plc - Intensity Therapeutics Treats First Patient
RNS Number: 5219 G SalvaRx Group plc 30 May 2017 SalvaRx Group PLC Intensity Therapeutics Treats First Patient SalvaRx is pleased to notify that Intensity Therapeutics Inc., in which the Company has an 8.5 per cent interest, has announced that the first patient has been dosed with INT230-6 as part of a Phase 1/ 2 international clinical study.
RNS Number: 5219 G SalvaRx Group plc 30 May 2017 SalvaRx Group PLC Intensity Therapeutics Treats First Patient SalvaRx is pleased to notify that Intensity Therapeutics Inc., in which the Company has an 8.5 per cent interest, has announced that the first patient has been dosed with INT230-6 as part of a Phase 1/ 2 international clinical study.